Free Trial
NASDAQ:NURO

NeuroMetrix (NURO) Stock Price, News & Analysis

NeuroMetrix logo
$4.41 +0.04 (+0.92%)
Closing price 03:51 PM Eastern
Extended Trading
$4.42 +0.01 (+0.23%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NeuroMetrix Stock (NASDAQ:NURO)

Key Stats

Today's Range
$4.35
$4.43
50-Day Range
$3.93
$4.45
52-Week Range
$2.66
$4.73
Volume
4,925 shs
Average Volume
17,962 shs
Market Capitalization
$9.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Remove Ads

NeuroMetrix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
8th Percentile Overall Score

NURO MarketRank™: 

NeuroMetrix scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for NeuroMetrix.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeuroMetrix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeuroMetrix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NeuroMetrix has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about NeuroMetrix's valuation and earnings.
  • Percentage of Shares Shorted

    0.16% of the float of NeuroMetrix has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroMetrix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroMetrix has recently increased by 78.57%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    NeuroMetrix does not currently pay a dividend.

  • Dividend Growth

    NeuroMetrix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.16% of the float of NeuroMetrix has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroMetrix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeuroMetrix has recently increased by 78.57%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    NeuroMetrix has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for NeuroMetrix this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, NeuroMetrix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.30% of the stock of NeuroMetrix is held by insiders.

  • Percentage Held by Institutions

    Only 19.40% of the stock of NeuroMetrix is held by institutions.

  • Read more about NeuroMetrix's insider trading history.
Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Stock News Headlines

NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com
Your Wealth is Under Attack
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Neurometrix Announces Board Changes for 2024
NeuroMetrix announces Bradley Fluegel to resign from Board
See More Headlines

NURO Stock Analysis - Frequently Asked Questions

NeuroMetrix's stock was trading at $3.97 at the beginning of 2025. Since then, NURO stock has increased by 11.1% and is now trading at $4.41.
View the best growth stocks for 2025 here
.

NeuroMetrix, Inc. (NASDAQ:NURO) announced its quarterly earnings results on Tuesday, November, 5th. The medical device company reported ($0.75) earnings per share for the quarter. The medical device company had revenue of $0.59 million for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative trailing twelve-month return on equity of 42.56%.

NeuroMetrix's stock reverse split on the morning of Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

NeuroMetrix's top institutional investors include GTS Securities LLC (1.12%) and Renaissance Technologies LLC (0.57%).
View institutional ownership trends
.

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroMetrix investors own include AMC Entertainment (AMC), NIO (NIO), Digital World Acquisition (DWAC), Meta Platforms (META), Advanced Micro Devices (AMD), Pfizer (PFE) and Tesla (TSLA).

Company Calendar

Last Earnings
11/05/2024
Today
3/17/2025
Next Earnings (Estimated)
3/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NURO
Employees
20
Year Founded
1996

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,530,000.00
Net Margins
-203.71%
Pretax Margin
-203.69%

Debt

Sales & Book Value

Annual Sales
$3.77 million
Price / Cash Flow
N/A
Book Value
$13.18 per share
Price / Book
0.33

Miscellaneous

Free Float
1,903,000
Market Cap
$9.03 million
Optionable
Not Optionable
Beta
2.15

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:NURO) was last updated on 3/17/2025 by MarketBeat.com Staff
From Our Partners